Dietary sodium, aldosterone, and left ventricular mass changes during long-term inhibition of the renin-angiotensin system

Hypertension

Volumn 56, Issue 5, 2010, Pages 865-870

  Du Cailar, Guilhem ^a   Fesler, Pierre ^a   Ribstein, Jean ^a   Mimran, Albert ^a  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

aldosterone; hypertension; left ventricular hypertrophy; renin angiotensin blockade; sodium intake

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SODIUM;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; ECHOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; HEART INDEX; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEX DETERMINATION; SODIUM INTAKE; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE; ANALYSIS OF VARIANCE; BLOOD; BLOOD PRESSURE; DRUG EFFECT; ECHOCARDIOGRAPHY; FOLLOW UP; HYPERTENSION; MIDDLE AGED; PATHOPHYSIOLOGY; STATISTICAL MODEL;

ADULT; AGED; ALDOSTERONE; ANALYSIS OF VARIANCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LINEAR MODELS; MALE; MIDDLE AGED; RENIN-ANGIOTENSIN SYSTEM; SODIUM, DIETARY;

EID: 78149235548     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.159277     Document Type: Article

References (42)

1. Devereux RB, Alderman MH. Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation. 1993;88:1444-1455.
2. Verdecchia P, Angeli F, Borgioni C, Gattobigio R, de Simone G, Devereux RB, Porcellati C. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens. 2003;16:895-899.
3. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlöf B. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 2004;292:2396-2398.
4. Muiesan ML, Salvetti M, Monteduro C, Bonzi B, Paini A, Viola S, Poisa P, Rizzoni D, Castellano M, Agabiti-Rosei E. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension. 2004;43:731-738.
5. Mancia G, Carugo S, Grassi G, Lanzarotti A, Schiavina R, Cesana G, Sega R, for the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) Study. Prevalence of left ventricular hypertrophy in hypertensive patients without and with blood pressure control: data from the PAMELA population. Hypertension. 2002;39:744-749.
6. de Simone G, Pasanisi F, Contaldo F. Link of nonhemodynamic factors to hemodynamic determinants of left ventricular hypertrophy. Hypertension. 2001;38:13-18.
7. Schmieder RE, Messerli FH, Garavaglia GE, Nunez BS. Salt intake as a determinant of cardiac involvement in essential hypertension. Circulation. 1988;78:951-956.
8. du Cailar G, Ribstein J, Daures JP, Mimran A. Sodium and left ventricular mass in untreated hypertensive and normotensive subjects. Am J Physiol. 1992;263:H177-H181.
9. Dhingra R, Pencina MJ, Benjamin EJ, Levy D, Larson MG, Meigs JB, Rifai N, D'Agostino RB Sr, Vasan RS. Cross-sectional relations of urinary sodium excretion to cardiac structure and hypertrophy: the Framingham Heart Study. Am J Hypertens. 2004;17:891-896. (Pubitemid 39361661)
10. Liebson PR, Grandits GA, Prineas RJ Grimm RH Jr, Neaton JD, Stamler J, Grimm RH Jr, Neaton JD, Stamler J. Echocardiographic correlates of left ventricular structure among 844 midly hypertensive men and women in the Treatment of Mild Hypertension Study (TOMHS). Circulation. 1993;87:476-486.
11. du Cailar G, Ribstein J, Mimran A. Dietary sodium and target organ damage in essential hypertension. Am J Hypertens. 2002;15:222-229.
12. du Cailar G, Mimran A, Fesler P, Ribstein J, Blacher J, Safar ME. Dietary sodium and pulse pressure in normotensive and essential hypertensive subjects. J Hypertens. 2004;22:697-703.
13. Mulè G, Nardi E, Cusimano P, Cottone S, Seddio G, Geraci C, Palermo A, Andronico G, Cerasola G. Plasma aldosterone and its relationships with left ventricular mass in essential hypertensive patients with the metabolic syndrome. Am J Hypertens. 2008;21:1055-1061.
14. El-Gharbawy AH, Nadig VS, Kotchen JM, Grim CE, Sagar KB, Kaldunski M, Hamet P, Pausova Z, Gaudet D, Gossard F, Kotchen TA. Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. Hypertension. 2001;37:845-850.
15. Vasan RS, Evans JC, Benjamin EJ, Levy D, Larson MG, Sundstrom J, Murabito JM, Sam F, Colucci WS, Wilson PW. Relations of serum aldosterone to cardiac structure: gender-related differences in the Framingham Heart Study. Hypertension. 2004;43:936-937.
16. Delles C, Schmidt BM, Müller HJ, Oehmer S, Klingbeil AU, Schmieder RE. Functional relevance of aldosterone for the determination of left ventricular mass. Am J Cardiol. 2003;91:297-301.
17. Jin Y, Kuznetsova T, Maillard M, Richart T, Thijs L, Bochud M, Herregods MC, Burnier M, Fagard R, Staessen JA. Independent relations of left ventricularstructure with the 24-hour urinary excretion of sodium and aldosterone. Hypertension. 2009;54:489-495.
18. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med. 1992;120:893-901.
19. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol (Heart Circ Physiol). 2002;283:H1802-H1810.
20. Cordaillat M, Rugale C, Casellas D, Mimran A, Jover B. Cardiorenal abnormalities associated with high sodium intake: correction by spironolactone in rats. Am J Physiol (Regul Integr Comp Physiol). 2005;289:R1137-R1143.
21. Jula AM, and Karanko KM. Effects on left ventricular hypertrophy of long-term nonpharmacological treatment with sodium restriction in mildto-moderate essential hypertension. Circulation. 1994;89:1023-1031.
22. Liebson PR, Grandits GA, Dianzumba S, Prineas RJ, Grimm RH Jr, Neaton JD, Stamler J. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation. 1995;91:698-706.
23. Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Aban I, Oparil S, Calhoun DA. Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. Hypertension. 2008;51:339-344.
24. Staessen J, Broughton PMG, Fletcher AE, Markowe HLJ, Marmot MG, Rose G, Semmence A, Shipley MJ, Bulpitt CJ. The assessment of the relationship between blood pressure and sodium intake using whole-day, daytime and overnight urine collections. J Hypertens. 1991;9:1035-1040.
25. Fesler P, Ribstein J, du Cailar G, Mimran A. Determinants of cardio-renal damage progression in normotensive and never-treated hypertensive subjects. Kidney Int. 2005;67:1974-1979.
26. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Circulation. 1977;55:613-618.
27. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41-46.
28. Devereux RB, Dahlöf B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris KE, Edelman JM, Wachtell K. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Trial. Circulation. 2004 14; 110:1456-1462. (Pubitemid 39238023)
29. Artham SM, Lavie CJ, Milani RV, Patel DA, Verma A, Ventura HO. Clinical impact of left ventricular hypertrophy and implications for regression. Prog Cardiovasc Dis. 2009;52:153-167.
30. Verdecchia P, Angeli F, Gattobigio R, Guerrieri M, Benemio G, Porcellati C. Does the reduction in systolic blood pressure alone explain the regression of left ventricular hypertrophy? J Hum Hypertens. 2004;18(suppl 2):S23-S28.
31. Luft FC, Fineberg NS, Sloan RS. Estimating dietary sodium intake in individuals receiving a randomly fluctuating intake. Hypertension. 1982;4:805-808.
32. Sanchez-Castillo CP, Warrender S, Whitehead TP, James WP. An assessment of the sources of dietary salt in a British population. Clin Sci (Lond). 1987;72:95-102.
33. Bing RF, Thrurston, Swales JD. Salt intake and diuretic treatment of hypertension. Lancet. 1979;21:121-123.
34. Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H. Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy. Endocrinology. 2000;141:1901-1904.
35. Fox CS, Larson MG, Hwang SJ, Leip EP, Rifai N, Levy D, Benjamin EJ, Murabito JM, Meigs JB, Vasan RS. Cross-sectional relations of serum aldosterone and urine sodium excretion to urinary albumin excretion in a community-based sample. Kidney Int. 2006;69:2064-2069.
36. Laverman GD, Andersen S, Rossing P, Navis G, de Zeeuw D, Parving HH. Renoprotection with and without blood pressure reduction. Kidney Int. 2005;67(suppl): s54-s59.
37. Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int. 2005;68:1190-1198.
38. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol. 1981;91:457-465.
39. Sato A, Saruta T. Aldosterone breakthrough during angiotensinconverting enzyme inhibitor therapy. Am J Hypertens. 2003;16:781-788.
40. Gaddam K, Corros C, Pimenta E, Ahmed M, Denney T, Aban I, Inusah S, Gupta H, Lloyd SG, Oparil S, Husain A, Dell'Italia LJ, Calhoun DA. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension. 2010;55:1137-1142.
41. Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell'Italia LJ, Calhoun DA. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009;54:475-481.
42. Bibbins-Domingo K, Chertow GM, Coxson PG, Moran A, Lightwood JM, Pletcher MJ, Goldman L. Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med. 2010;362:590-599.